{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(2)"],"submitter":["Reinmuth N"],"pubmed_abstract":["Introduction
In the phase 3 EVOKE-01 trial (NCT05089734), sacituzumab govitecan (SG) exhibited a numerical improvement in overall survival and tolerability compared with docetaxel in patients with metastatic NSCLC previously treated with platinum-based chemotherapy and programmed cell death protein (ligand) 1 inhibitors, although results were not statistically significant. This analysis evaluated health-related quality of life (HRQoL) data from EVOKE-01.Methods
Patients (N = 603) were randomized 1:1 to SG (n = 299) or docetaxel (n = 304) in 21-day cycles. HRQoL was assessed by the NSCLC Symptom Assessment Questionnaire (NSCLC-SAQ), European Organization for Research and Treatment of Cancer Quality of Life questionnaire-Core 30 (QLQ-C30), and EuroQol 5 Dimension 3-level ques"],"journal":["JTO clinical and research reports"],"pagination":["100929"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12828819"],"repository":["biostudies-literature"],"pubmed_title":["Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial."],"pmcid":["PMC12828819"],"pubmed_authors":["Couraud S","Zhang E","Baijal S","Paz-Ares L","Garassino MC","Felip E","Guo S","Kato T","Parra HS","Radford M","Pelligra CG","Reinmuth N","Garrido P","Mekan S","Daniel D","Percent I","Rittmeyer A","Patel M"],"additional_accession":[]},"is_claimable":false,"name":"Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial.","description":"Introduction
In the phase 3 EVOKE-01 trial (NCT05089734), sacituzumab govitecan (SG) exhibited a numerical improvement in overall survival and tolerability compared with docetaxel in patients with metastatic NSCLC previously treated with platinum-based chemotherapy and programmed cell death protein (ligand) 1 inhibitors, although results were not statistically significant. This analysis evaluated health-related quality of life (HRQoL) data from EVOKE-01.Methods
Patients (N = 603) were randomized 1:1 to SG (n = 299) or docetaxel (n = 304) in 21-day cycles. HRQoL was assessed by the NSCLC Symptom Assessment Questionnaire (NSCLC-SAQ), European Organization for Research and Treatment of Cancer Quality of Life questionnaire-Core 30 (QLQ-C30), and EuroQol 5 Dimension 3-level ques","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-06-06T22:36:44.751Z","creation":"2026-06-06T03:10:47.726Z"},"accession":"S-EPMC12828819","cross_references":{"pubmed":["41584718"],"doi":["10.1016/j.jtocrr.2025.100929"]}}